DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

A Study of Abemaciclib in Recurrent Glioblastoma

Phase 2

Active, not recruiting

Conditions: Glioblastoma

Interventions: Drug: Abemaciclib
Procedure: Surgery

First Posted Date: 2016-12-05

Last Posted Date: 2024-07-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT02981940

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States

and more 4 locations

Reduction of Post Mastectomy Pain With the Jacki® Recovery Jacket

Not Applicable

Completed

Conditions: Mastectomy

Interventions: Other: Standard Care Pain medicine/management
Device: Jacki Recovery jacket

First Posted Date: 2016-11-29

Last Posted Date: 2020-03-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 139

Registration Number: NCT02976103

Locations: 🇺🇸
Brigham and Women's Faulkner Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Pembrolizumab in Refractory Advanced Esophageal Cancer

Phase 2

Completed

Conditions: Adenocarcinoma Esophagus
Esophageal Cancer
Squamous Cell Esophagus Cancer

Interventions: Drug: Pembrolizumab

First Posted Date: 2016-11-23

Last Posted Date: 2023-09-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 49

Registration Number: NCT02971956

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Improving Communication Between Cancer Patients & Oncologists

Not Applicable

Completed

Conditions: Cancer

Interventions: Behavioral: Enhanced SCOPE training
Behavioral: Standard Communication training

First Posted Date: 2016-11-21

Last Posted Date: 2020-01-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 148

Registration Number: NCT02969031

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Device: Supine MRI
Other: Neoadjuvant Therapy (NAT)
Device: Ultrasound
Device: Mammography
Procedure: Standard of Care
Device: Standard MRI

First Posted Date: 2016-11-06

Last Posted Date: 2024-03-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 57

Registration Number: NCT02956473

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes

Not Applicable

Active, not recruiting

Conditions: Li-Fraumeni Syndrome

Interventions: Device: Whole Body MRI

First Posted Date: 2016-11-01

Last Posted Date: 2025-01-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 150

Registration Number: NCT02950987

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Pembrolizumab in Metastatic Anal Cancer

Phase 2

Completed

Conditions: Anal Cancer

Interventions: Drug: Pembrolizumab

First Posted Date: 2016-09-30

Last Posted Date: 2023-06-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 38

Registration Number: NCT02919969

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 1 locations

Merestinib In Non-Small Cell Lung Cancer And Solid Tumors

Phase 2

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung
Solid Tumor

Interventions: Drug: Merestinib

First Posted Date: 2016-09-30

Last Posted Date: 2024-04-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT02920996

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

Phase 2

Active, not recruiting

Conditions: Head and Neck Cancer

Interventions: Drug: Nivolumab
Procedure: Standard of Care Surgery
Drug: Ipilimumab

First Posted Date: 2016-09-29

Last Posted Date: 2025-01-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT02919683

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma

Not Applicable

Completed

Conditions: Non-Hodgkin's Lymphoma
Multiple Myeloma

Interventions: Dietary Supplement: Placebo
Dietary Supplement: Enterade
Other: Standard Supportive Care

First Posted Date: 2016-09-29

Last Posted Date: 2023-03-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 114

Registration Number: NCT02919670

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy